Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Vermillion Supports First World Ovarian Cancer Day

Published: Thursday, May 16, 2013
Last Updated: Thursday, May 16, 2013
Bookmark and Share
Vermillion offers women new hope with OVA1, a FDA-cleared test designed to aid in the prediction of malignancy prior to surgery on an ovarian mass.

Vermillion, Inc. joins ovarian cancer organizations around the world in recognizing May 8 as World Ovarian Cancer Day.

On this day, ovarian cancer organizations are uniting to educate their communities about ovarian cancer and its symptoms. For women living with the disease, and their families and friends, World Ovarian Cancer Day represents a global expression of solidarity in the fight against the disease.

"We commend the organizers of this First World Ovarian Cancer Day for bringing together 26 ovarian cancer organizations across 17 countries to generate greater awareness about this deadly disease," said Thomas McLain, Vermillion's president and chief executive officer.

McLain continued, "Given the lethality of ovarian cancer and how often it goes undetected before it's too late, we need to increase public knowledge about its symptoms as well as the critical importance of early and appropriate treatment."

According to Ovariancancerday.org, every year ovarian cancer is diagnosed in nearly a quarter of a million women around the world, leading to 140,000 cancer-related deaths.

In the U.S., out of the 22,000 women who are diagnosed with ovarian cancer every year, 81% are diagnosed as malignant only after the cancer had spread to other parts of the body (metastases).

However, only one in three women with ovarian cancer are initially treated by a gynecologic oncologist, in part due to inadequate diagnostic tests and procedures. These statistics reveal how early detection and proper treatment by a gynecologic oncologist can be the key to survival.

Recent stories in the media have highlighted the deficiencies in the detection and treatment of ovarian cancer, including coverage by the New York Times and NBC Nightly News.

According to Dr. Bristow, the director of gynecologic oncology services at UC Irvine Healthcare and principal investigator of the study highlighted in these articles, "If we could just make sure that women get to the people who are trained to take care of them, the impact would be much greater than that of any new chemotherapy drug or biological agent."

Vermillion, which has been dedicated to addressing these deficiencies, has achieved remarkable results with its OVA1® test, the first FDA-cleared test designed to aid in the prediction of malignancy prior to surgery on an ovarian mass.

Vermillion developed the OVA1 test together with Johns Hopkins University after nearly a decade of proteomic research. In two published clinical studies, OVA1 demonstrated 96% sensitivity across a broad range of ovarian malignancies and detected over 90% of all early stage ovarian cancers.

The studies also reported a 95%-98% negative predictive value, a critical feature for minimizing the likelihood that a non-oncology surgeon discovers ovarian cancer during surgery.

The powerful performance of OVA1 helps to ensure that women with ovarian cancer are treated by a gynecologic oncologist, which is a critical determinant of survival.

Since receiving FDA clearance in 2009, Vermillion has worked to increase insurance coverage for the test, as well as greater use by physicians.

"Despite the strong progress we've made, with more than 42,000 test performed to-date, the adoption rate of OVA1 has been far too slow," noted McLain "We are hopeful that a special day dedicated to building ovarian cancer awareness can help bring about the changes we need in healthcare policy, insurance coverage and guidelines which would better support OVA1 as the standard of care in the diagnosis and treatment of ovarian cancer."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Vermillion Awarded $7.5M Grant
The grant awarded is to aid the development of a multi-site pelvic mass registry.
Friday, May 22, 2015
New Clinical Study on the Relationship Between Imaging and OVA1®
New analysis explores interactions between clinical risk factors used in pre-surgical assessment.
Friday, March 21, 2014
Vermillion Reports Fourth Quarter and Full Year 2013 Results
Company will next pursue a national price for its OVA1 test in 2014.
Saturday, March 08, 2014
American Journal of Obstetrics & Gynecology Publishes New Clinical Study of OVA1 Test
Significantly superior early-stage sensitivity shown versus CA125, modified ACOG guidelines or overall clinical assessment in premenopausal and postmenopausal women planning surgery.
Thursday, November 14, 2013
Vermillion's OVA1 Receives New Statement by SGO
OVA1® has received new statement on clinical validation and medical use.
Tuesday, July 16, 2013
Vermillion Reports First Quarter 2013 Results
Building upon early success of OVA1, recent funding sets stage for 2013-2015 strategic plan.
Thursday, May 16, 2013
U.S. Army and Vermillion Sign Cooperative Research and Development Agreement
U.S. Army and Vermillion to assess health and economic benefits of OVA1 as a standard of care.
Friday, April 19, 2013
Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study
Outstanding performance reported in early-stage ovarian cancer and across broad range of malignancy subtypes.
Friday, December 28, 2012
Vermillion Receives Notice of Allowance from USPTO
Company receives notice of allowance for patent on methods for diagnosing ovarian cancer.
Thursday, September 27, 2012
Vermillion Receives Notice of Allowance for Patent of Biomarker for Ovarian Cancer
Patent makes claims in the uses of urinary sMAP in the diagnosis of ovarian cancer.
Tuesday, July 24, 2012
Vermillion Receives Notice of Allowance for Patent on Platelet Biomarkers of Angiogenesis
Patented biomarkers used to measure ongoing angiogenic activity.
Tuesday, March 06, 2012
Vermillion Completes the Acquisition of Correlogic Systems' Ovarian Cancer Diagnostics Business for $435,000
The assets include more than 1,000 prospectively collected diagnostic samples from ovarian tumor studies, three biomarker-related pending U.S. patents, proprietary software and other intellectual property.
Thursday, December 22, 2011
Vermillion Announces Issuance of Patent for Lung Cancer
The United States Patent and Trademark Office (USPTO) has issued patent number 8,014,952 entitled " Serum Biomarkers in Lung Cancer " to the Company.
Thursday, September 08, 2011
Vermillion Announces Presentation of Positive Ovarian Biomarker Data for Next Generation Test
Results presented by collaborators at Johns Hopkins University School of Medicine at the 42nd Annual Meeting in Orlando, Florida.
Thursday, March 10, 2011
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!